Purchase this article with an account.
Y. Roh; Ranibizumab for Occult and Classic Choroidal Neovascualr Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2674. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the efficacy of intravitreal injection of ranibizumab(Lucentis) in the treatment of occult and classic type chroidal neovascular age-related macula degeneration(AMD)
In this retrospective reviews of 106 eyes in 96 patients, patients were divided into two groups, occult type(38 eyes, 35.84%) and classic type(68 eyes, 64.15%). Both Patient group received 3 injections at monthly intervals of intravitreal ranibizumab(0.5mg) and additional injection as needed after the baseline injection. For the comparison of two groups, the serial changes in best corrected visual acuity(BCVA) and optical coherence tomography(OCT) were measured at the first week and then monthly intervals for consecutive 10 months.
In the classic type group, the baseline mean BCVA LogMAR scale was 0.88, and the mean BCVA after 3 ranibizumab injections was improved to 0.79. In the occult type group, the mean BCVA was improved from 0.92 to 0.84. The improvement in visual acuity of classic type group didn't exhibit any statistically significant difference as compared to occult group.(Student t-test, P>0.05) In the classic type group, the mean OCT central foveal thickness(CFT) was reduced from 400.1um to 312.0um after Lucentis injections. In the occult type group, the mean CFT was reduced from 398.6 to 323.4um. The reduce in macular thickness of classic type group also didn't exhibit any statistically significant difference as compared to occult group.(Student t-test, P>0.05).
Intravitreal ranibizumab injections were effective treatment for both of the classic and occult choroidal neovascularization in age-related macular degeneration. However, the efficacy of treatment in the classic type CNV as compared to occult type were not statistically significant
This PDF is available to Subscribers Only